MDC EYESIS participated in 25th National Ophthalmology Academic Conference

On November 20, 2020, the 25th National Ophthalmology Academic Conference of the Chinese Medical Association was held in Xiamen. Due to the special situation of COVID-19 epidemic prevention and control, the online and offline gathering amount was adopted, which greatly reduced the number of offline participants. Even so, thousands of ophthalmology colleagues and hundreds of ophthalmology companies gathered in XiaMen for the annual ophthalmology event.

As the representative of the exhibitors, MDC Medical launched the fourth generation of Eyesis equipment for dry eye treatment, which was once again presented at the 25th National Ophthalmology Academic Conference of the Chinese Medical Association. During the product exhibition meeting, the Eyesis meibomian gland dysfunction therapeutic apparatus is mainly used for dry eye treatment, and is a light pulse equipment specially used for the treatment of meibomian gland dysfunction.

In addition, after strict testing and approval by the State Food and Drug Administration, The fourth generation IPL medical equipment of MDC has the advantages of "being used for the treatment of meibomian gland dysfunction "The safety and effectiveness of the registration certificate of the indications have been supported by the corresponding clinical trials, with higher safety. At the exhibition site, senior ophthalmologists such as Shi Weiyun and Gao Hua, Dean of Shandong Eye Hospital, Yan Xiaoming, Dean of Peking University First Hospital, Zhao Shaozhen, Dean of Tianjin Medical University Eye Hospital, and Wu Jie, Dean of Xi'an First Hospital conducted in-depth consultation, discussion and trial of MDC's products.

As the first innovative enterprise in China based on dry eye treatment and integrating R&D, production and sales, "MDC Medical" has always adhered to the enterprise concept of "based on dry eye and continuous innovation" to benefit dry eye patients and serve the clinic. In the future, MDC Medical will continue to develop new equipment to bring new technologies and products to ophthalmology.